TY - JOUR T1 - Therapeutic Window for Phosphodiesterase 6-Related Retinitis Pigmentosa. JF - JAMA Ophthalmol Y1 - 2019 A1 - Wang, Nan-Kai A1 - Mahajan, Vinit B A1 - Tsang, Stephen H KW - Cone-Rod Dystrophies KW - Cyclic Nucleotide Phosphodiesterases, Type 6 KW - Eye Proteins KW - Follow-Up Studies KW - Humans KW - Mutation KW - Retinitis Pigmentosa VL - 137 IS - 6 ER - TY - JOUR T1 - Chronic Recurrent Pseudophakic Endophthalmitis. JF - JAMA Ophthalmol Y1 - 2016 A1 - Chin, Eric K A1 - Almeida, David R P A1 - Mahajan, Vinit B KW - Aged, 80 and over KW - Chronic Disease KW - Combined Modality Therapy KW - Drug Therapy, Combination KW - Endophthalmitis KW - Female KW - Follow-Up Studies KW - Humans KW - Mycobacterium chelonae KW - Mycobacterium Infections, Nontuberculous KW - Recurrence KW - Risk Assessment KW - Slit Lamp KW - Treatment Outcome KW - Vancomycin KW - Vitrectomy VL - 134 IS - 4 U1 - http://www.ncbi.nlm.nih.gov/pubmed/26868359?dopt=Abstract ER - TY - JOUR T1 - Precision Medicine: Personalized Proteomics for the Diagnosis and Treatment of Idiopathic Inflammatory Disease. JF - JAMA Ophthalmol Y1 - 2016 A1 - Velez, Gabriel A1 - Roybal, C Nathaniel A1 - Colgan, Diana A1 - Tsang, Stephen H A1 - Bassuk, Alexander G A1 - Mahajan, Vinit B KW - Adrenal Cortex Hormones KW - Adult KW - Analysis of Variance KW - Case-Control Studies KW - Cytokines KW - Follow-Up Studies KW - Humans KW - Immunosuppressive Agents KW - Male KW - Middle Aged KW - Precision Medicine KW - Proteomics KW - Reference Values KW - Risk Assessment KW - Severity of Illness Index KW - Treatment Outcome KW - Uveitis KW - Visual Acuity AB -

IMPORTANCE: To better characterize posterior uveitis, vitreous samples from 15 patients were subjected to antibody arrays, and the expression levels of 200 human cytokines were evaluated. Expression was analyzed by 1-way analysis of variance (significance at P < .01), unsupervised cluster algorithm, and pathway analysis.

OBSERVATIONS: Unbiased clustering of patients, based on their cytokine expression profile, suggested that particular protein networks and molecular pathways are altered in various forms of uveitis. Expression of interleukin 23 (IL-23), IL-1 receptor I (IL-1RI), IL-17R, tissue inhibitors of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2), insulinlike growth factor-binding protein 2 (IGFBP-2), nerve growth factor (b-NGF), platelet-derived growth factor receptor β polypeptide (PDGFRb), bone morphogenic protein 4 (BMP-4), and stem cell factor (SCF) constituted a common cytokine signature in the vitreous of patients with uveitis. In 1 patient with progressive, idiopathic visual loss, this last-line analysis implicated retinal autoimmunity, a diagnosis that was validated when her serum sample was found to contain antibodies to S-arrestin, a retinal protein and potent cause of autoimmune retinal degeneration.

CONCLUSIONS AND RELEVANCE: The analysis identifies a common cytokine signature for posterior uveitis and guides the diagnosis of a patient with idiopathic uveitis. Personalized treatment reversed the visual loss, illustrating how proteomic tools may individualize therapy.

VL - 134 IS - 4 U1 - http://www.ncbi.nlm.nih.gov/pubmed/26848019?dopt=Abstract ER - TY - JOUR T1 - Intraoperative sclerotomy-related retinal breaks during 23-gauge pars plana vitrectomy. JF - Retina Y1 - 2013 A1 - Tarantola, Ryan M A1 - Tsui, Janet Y A1 - Graff, Jordan M A1 - Russell, Stephen R A1 - Boldt, H Culver A1 - Folk, James C A1 - Mahajan, Vinit B KW - Aged KW - Aged, 80 and over KW - Female KW - Follow-Up Studies KW - Humans KW - Incidence KW - Intraoperative Complications KW - Male KW - Microsurgery KW - Middle Aged KW - Postoperative Complications KW - Retinal Detachment KW - Retinal Perforations KW - Retrospective Studies KW - Sclerostomy KW - Tomography, Optical Coherence KW - Visual Acuity KW - Vitrectomy AB -

PURPOSE: To study the incidence and characteristics of intraoperative sclerotomy-related retinal breaks encountered during 23-gauge pars plana vitrectomy.

METHODS: A retrospective consecutive case series was assembled from the surgical logs and charts of patients who underwent 23-gauge pars plana vitrectomy. Demographic data and preoperative, intraoperative, and postoperative records were examined.

RESULTS: A total 548 eyes met the inclusion criteria. Of them, 145 eyes underwent pars plana vitrectomy for repair of a rhegmatogenous retinal detachment (RRD) and 403 eyes for other indications. Sclerotomy-related retinal breaks were found in 8 of 548 (1.45%) eyes. No breaks were found in the 145 RRD eyes. In non-RRD cases, 8 of 403 (1.98%) eyes had sclerotomy-related breaks. All breaks were adjacent to the superior sclerotomies. The incidence of postoperative retinal detachment was 0% (0 of 403) in the non-RRD group. In eyes with breaks, the primary surgical indication was vitreomacular traction in six of eight eyes and epiretinal membrane in two of eight eyes. Posterior vitreous detachment was absent in six of eight eyes, and six of eight eyes were phakic. Eyes with vitreomacular traction had a significantly higher incidence of breaks (P < 0.0001). Eyes with a surgical indication other than RRD had a higher incidence of breaks, but this was not statistically significant when compared with eyes with RRD (P = 0.087).

CONCLUSION: Pars plana vitrectomy (23-gauge) is associated with a low incidence of sclerotomy-related retinal breaks and postoperative retinal detachments. Eyes with breaks are more likely to be phakic and without a preoperative posterior vitreous detachment. The presence of vitreomacular traction may be a risk factor for the development of intraoperative sclerotomy-related breaks.

VL - 33 IS - 1 U1 - http://www.ncbi.nlm.nih.gov/pubmed/22791174?dopt=Abstract ER - TY - JOUR T1 - Bilateral intravitreal injection of antivascular endothelial growth factor therapy. JF - Retina (Philadelphia, Pa.) Y1 - 2011 A1 - Mahajan, Vinit B A1 - Elkins, Kori A A1 - Russell, Stephen R A1 - Boldt, H Culver A1 - Gehrs, Karen M A1 - Weingeist, Thomas A A1 - Stone, Edwin M A1 - Abràmoff, Michael D A1 - Liu, Dawei A1 - Folk, James C KW - Aged KW - Aged, 80 and over KW - Antibodies, Monoclonal KW - Case-Control Studies KW - Drug Administration Schedule KW - Drug Combinations KW - Female KW - Follow-Up Studies KW - Humans KW - Incidence KW - Injections, Intraocular KW - Macular Degeneration KW - Male KW - Middle Aged KW - Myocardial Infarction KW - Patient Preference KW - Retrospective Studies KW - Vascular Endothelial Growth Factor A KW - Vitreous Body AB -

The purpose of this study was to review adverse events and patient preference after bilateral intravitreal injection of antibodies to vascular endothelial growth factor.

VL - 31 IS - 1 U1 - http://www.ncbi.nlm.nih.gov/pubmed/21187731?dopt=Abstract ER - TY - JOUR T1 - Effects of vitrectomy on age-related macular degeneration. JF - Ophthalmology Y1 - 2010 A1 - Roller, A Brock A1 - Mahajan, Vinit B A1 - Boldt, H Culver A1 - Abràmoff, Michael D A1 - Russell, Stephen R A1 - Folk, James C KW - Aged KW - Aged, 80 and over KW - Case-Control Studies KW - Choroidal Neovascularization KW - Disease Progression KW - Epiretinal Membrane KW - Female KW - Follow-Up Studies KW - Geographic Atrophy KW - Humans KW - Macular Degeneration KW - Male KW - Middle Aged KW - Pilot Projects KW - Retinal Perforations KW - Retrospective Studies KW - Visual Acuity KW - Vitrectomy AB -

To determine whether vitrectomy alters the long-term progression of age-related macular degeneration (AMD).

VL - 117 IS - 7 U1 - http://www.ncbi.nlm.nih.gov/pubmed/20176401?dopt=Abstract ER - TY - JOUR T1 - Intravitreal bevacizumab during pregnancy. JF - Retina (Philadelphia, Pa.) Y1 - 2010 A1 - Tarantola, Ryan M A1 - Folk, James C A1 - Boldt, H Culver A1 - Mahajan, Vinit B KW - Adult KW - Angiogenesis Inhibitors KW - Antibodies, Monoclonal KW - Choroidal Neovascularization KW - Eye Infections, Fungal KW - Female KW - Follow-Up Studies KW - Gestational Age KW - Histoplasmosis KW - Humans KW - Intravitreal Injections KW - Off-Label Use KW - Pregnancy KW - Pregnancy Complications KW - Sarcoidosis KW - Tomography, Optical Coherence KW - Uveitis KW - Vascular Endothelial Growth Factor A KW - Visual Acuity AB -

To report the clinical course of four women treated with intravitreal bevacizumab during pregnancy.

VL - 30 IS - 9 U1 - http://www.ncbi.nlm.nih.gov/pubmed/20924262?dopt=Abstract ER - TY - JOUR T1 - Management of sympathetic ophthalmia with the fluocinolone acetonide implant. JF - Ophthalmology Y1 - 2009 A1 - Mahajan, Vinit B A1 - Gehrs, Karen M A1 - Goldstein, Debra A A1 - Fischer, David H A1 - Lopez, Juan S A1 - Folk, James C KW - Adult KW - Aged KW - Drug Implants KW - Female KW - Fluocinolone Acetonide KW - Follow-Up Studies KW - Glucocorticoids KW - Humans KW - Immunosuppressive Agents KW - Intraocular Pressure KW - Male KW - Middle Aged KW - Ophthalmia, Sympathetic KW - Retrospective Studies KW - Treatment Outcome KW - Visual Acuity AB -

We examined whether implantation of the fluocinolone acetonide (Retisert) implant achieved control of inflammation and a reduced need for oral corticosteroids or immunosuppressives in patients with sympathetic ophthalmia (SO).

VL - 116 IS - 3 U1 - http://www.ncbi.nlm.nih.gov/pubmed/19147232?dopt=Abstract ER -